Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2007 3
2008 1
2009 1
2010 5
2011 1
2013 3
2014 5
2015 5
2016 8
2017 11
2018 11
2019 9
2020 14
2021 12
2022 23
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.
Shukla S, Li D, Nguyen H, Conner J, Bayshtok G, Cho WH, Pachai M, Teri N, Campeau E, Attwell S, Trojer P, Ostrovnaya I, Gopalan A, Corey E, Chi P, Chen Y. Shukla S, et al. Among authors: chi p. bioRxiv [Preprint]. 2024 Mar 13:2024.03.09.584256. doi: 10.1101/2024.03.09.584256. bioRxiv. 2024. PMID: 38559135 Free PMC article. Preprint.
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Heinrich MC, et al. Among authors: chi p. Nat Med. 2024 Feb;30(2):498-506. doi: 10.1038/s41591-023-02734-5. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182785 Free PMC article. Clinical Trial.
Activating neutrophils by co-administration of immunogenic recombinant modified vaccinia virus Ankara and granulocyte colony-stimulating factor for the treatment of malignant peripheral nerve sheath tumor.
Wang Y, Liu S, Yan J, Baseer-Tariq S, Salla B, Ji L, Li M, Chi P, Deng L. Wang Y, et al. Among authors: chi p. bioRxiv [Preprint]. 2023 Nov 29:2023.11.29.569123. doi: 10.1101/2023.11.29.569123. bioRxiv. 2023. PMID: 38076896 Free PMC article. Preprint.
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas.
Rosenbaum E, Seier K, Bradic M, Kelly C, Movva S, Nacev BA, Gounder MM, Keohan ML, Avutu V, Chi P, Thornton KA, Chan JE, Dickson MA, Donoghue MTA, Tap WD, Qin LX, D'Angelo SP. Rosenbaum E, et al. Among authors: chi p. Cancer Res Commun. 2023 Oct 18;3(10):2118-2125. doi: 10.1158/2767-9764.CRC-22-0140. Cancer Res Commun. 2023. PMID: 37787759 Free PMC article.
An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort study.
Bertsimas D, Margonis GA, Tang S, Koulouras A, Antonescu CR, Brennan MF, Martin-Broto J, Rutkowski P, Stasinos G, Wang J, Pikoulis E, Bylina E, Sobczuk P, Gutierrez A, Jadeja B, Tap WD, Chi P, Singer S. Bertsimas D, et al. Among authors: chi p. EClinicalMedicine. 2023 Sep 9;64:102200. doi: 10.1016/j.eclinm.2023.102200. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37731933 Free PMC article.
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma.
Gleason CE, Dickson MA, Klein Dooley ME, Antonescu CR, Gularte-Mérida R, Benitez M, Delgado JI, Kataru RP, Tan MWY, Bradic M, Adamson TE, Seier K, Richards AL, Palafox M, Chan E, D'Angelo SP, Gounder MM, Keohan ML, Kelly CM, Chi P, Movva S, Landa J, Crago AM, Donoghue MTA, Qin LX, Serra V, Turkekul M, Barlas A, Firester DM, Manova-Todorova K, Mehrara BJ, Kovatcheva M, Tan NS, Singer S, Tap WD, Koff A. Gleason CE, et al. Among authors: chi p. Clin Cancer Res. 2024 Feb 16;30(4):703-718. doi: 10.1158/1078-0432.CCR-23-2378. Clin Cancer Res. 2024. PMID: 37695642 Free PMC article.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: chi p. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
119 results